Abstract:Antimicrobial resistance (AMR) is a global threat. A better understanding of how antibiotic use and between-ward patient transfers (or connectivity) impact population-level AMR in hospital networks can help optimize antibiotic stewardship and infection control strategies. Here, we used a metapopulation framework to explain variations in the incidence of infections caused by 7 major bacterial species and their drug-resistant variants in a network of 357 hospital wards. We found that ward-level antibiotic consum… Show more
“…While we were able to identify factors that associate with elevated or reduced levels of resistance at such large scales, we note that over shorter timescales and more localized spatial scales key factors may differ. For example, we did not find an effect of total drug use on resistance, but drug use is known to drive resistance increases at finer scales such as within individual hospitals or countries 30,52,53 . We also note that being an observational study, the associations identified here are not necessarily causative.…”
Section: Discussioncontrasting
confidence: 59%
“…In fact, our results demonstrate that among the various factors implicated in resistance evolution, being nosocomial is one of the most statistically robust predictors (Table 2). The high prevalence of antibiotic resistance among nosocomial pathogens is largely attributed to the interplay of high antibiotic usage, which may impose selection for resistance, and imperfect infection control practices, which may promote transmission of resistant pathogens in hospitals [29][30][31] . These results highlight the importance of developing protocols to further minimize pathogen transmission within hospitals, for example, by improving sterilization and hygiene practices.…”
Antibiotic resistance poses one of the greatest public health challenges of the 21st century. Yet not all pathogens are equally affected by resistance evolution. Why? Here we examine what underlies variation in antibiotic resistance across human bacterial pathogens and the drugs used to treat them. We document the observed prevalence of antibiotic resistance for ‘pathogen x drug’ combinations across 57 different human bacterial pathogens and 53 antibiotics from 15 drug classes used to treat them. Using AIC-based model selection we analyze 14 different traits of bacteria and antibiotics that are believed to be important in resistance evolution. Using these data, we identify the traits that best explain observed variation in resistance evolution. Our results show that nosocomial pathogens and indirectly transmitted pathogens are significantly associated with increased prevalence of resistance whereas zoonotic pathogens, specifically those with wild animal reservoirs, are associated with reduced prevalence of resistance. We found partial support for associations between drug resistance and gram classification, human microbiome reservoirs, horizontal gene transfer, and documented human-to human transfer. Global drug use, time since drug discovery, mechanism of drug action, and environmental reservoirs did not emerge as statistically robust predictors of drug resistance in our analyses. To the best of our knowledge this work is the first systematic analysis of resistance across such a wide range of human bacterial pathogens, encompassing the vast majority of common bacterial pathogens. Insights from our study may help guide public health policies and future studies on resistance control.
“…While we were able to identify factors that associate with elevated or reduced levels of resistance at such large scales, we note that over shorter timescales and more localized spatial scales key factors may differ. For example, we did not find an effect of total drug use on resistance, but drug use is known to drive resistance increases at finer scales such as within individual hospitals or countries 30,52,53 . We also note that being an observational study, the associations identified here are not necessarily causative.…”
Section: Discussioncontrasting
confidence: 59%
“…In fact, our results demonstrate that among the various factors implicated in resistance evolution, being nosocomial is one of the most statistically robust predictors (Table 2). The high prevalence of antibiotic resistance among nosocomial pathogens is largely attributed to the interplay of high antibiotic usage, which may impose selection for resistance, and imperfect infection control practices, which may promote transmission of resistant pathogens in hospitals [29][30][31] . These results highlight the importance of developing protocols to further minimize pathogen transmission within hospitals, for example, by improving sterilization and hygiene practices.…”
Antibiotic resistance poses one of the greatest public health challenges of the 21st century. Yet not all pathogens are equally affected by resistance evolution. Why? Here we examine what underlies variation in antibiotic resistance across human bacterial pathogens and the drugs used to treat them. We document the observed prevalence of antibiotic resistance for ‘pathogen x drug’ combinations across 57 different human bacterial pathogens and 53 antibiotics from 15 drug classes used to treat them. Using AIC-based model selection we analyze 14 different traits of bacteria and antibiotics that are believed to be important in resistance evolution. Using these data, we identify the traits that best explain observed variation in resistance evolution. Our results show that nosocomial pathogens and indirectly transmitted pathogens are significantly associated with increased prevalence of resistance whereas zoonotic pathogens, specifically those with wild animal reservoirs, are associated with reduced prevalence of resistance. We found partial support for associations between drug resistance and gram classification, human microbiome reservoirs, horizontal gene transfer, and documented human-to human transfer. Global drug use, time since drug discovery, mechanism of drug action, and environmental reservoirs did not emerge as statistically robust predictors of drug resistance in our analyses. To the best of our knowledge this work is the first systematic analysis of resistance across such a wide range of human bacterial pathogens, encompassing the vast majority of common bacterial pathogens. Insights from our study may help guide public health policies and future studies on resistance control.
“…Nonetheless, our goal was to study how ecological mechanisms impact average epidemiological outcomes in the context of different model assumptions and parameter uncertainty, and in this context, ODE modeling was the more appropriate tool, particularly for widely endemic ARB like C. difficile , MRSA and ESBL-EC. Still, further insights could certainly be gained by accounting for additional complexity and stochastic heterogeneity in future work, from within-host spatial organization ( Estrela et al, 2015 ), to patient and staff contact behavior ( Duval et al, 2019 ), to inter-institutional or inter-ward meta-population dynamics ( Shapiro et al, 2020 ). These distinctions may be particularly important for rare or non-endemic ARB (e.g.…”
Section: Discussionmentioning
confidence: 99%
“…(Niewiadomska et al, 2019) Here, microbiome competition was found to have a large impact on incidence but comparatively little impact on resistance ratesboth for the theoretical pathogen evaluated in Part 1 (Figures 3, 4) and for the four ARB (Estrela et al, 2015) to patient and staff contact behaviour, (Duval et al, 2019) to inter-institutional or inter-ward meta-population dynamics. (Shapiro et al, 2020) These distinctions may be particularly important for rare or nonendemic ARB (e.g. CP-KP in some regions).…”
Section: Microbiome Ecology Underlies Epidemiological Responses To Public Health Interventionsmentioning
The human microbiome can protect against colonization with pathogenic antibiotic-resistant bacteria (ARB), but its impacts on the spread of antibiotic resistance are poorly understood. We propose a mathematical modelling framework for ARB epidemiology formalizing within-host ARB-microbiome competition, and impacts of antibiotic consumption on microbiome function. Applied to the healthcare setting, we demonstrate a trade-off whereby antibiotics simultaneously clear bacterial pathogens and increase host susceptibility to their colonization, and compare this framework with a traditional strain-based approach. At the population level, microbiome interactions drive ARB incidence, but not resistance rates, reflecting distinct epidemiological relevance of different forces of competition. Simulating a range of public health interventions (contact precautions, antibiotic stewardship, microbiome recovery therapy) and pathogens (Clostridioides difficile, methicillin-resistant Staphylococcus aureus, multidrug-resistant Enterobacteriaceae) highlights how species-specific within-host ecological interactions drive intervention efficacy. We find limited impact of contact precautions for Enterobacteriaceae prevention, and a promising role for microbiome-targeted interventions to limit ARB spread.
“…Now, in eLife, Jean-Philippe Rasigade and co-workers from Université de Lyon and the Hospices Civils de Lyon – including Julie Teresa Shapiro as first author – report how seven species of bacteria, and their resistant strains, spread across 357 wards of a major hospital organisation in Lyon ( Shapiro et al, 2020 ). To do this, the team adapted a model that is often used in ecology to study populations of animal species that live in, and migrate between, different locations.…”
Moving patients between wards and prescribing high levels of antibiotics increases the spread of bacterial infections that are resistant to treatment in hospitals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.